The growth of the market is due to the rising prevalence of asthma and the increasing research activities and product innovations are propelling the asthma drugs market growth. However, the unmet medical needs are hampering market growth.
Asthma is a chronic respiratory condition marked by fluctuating airflow restriction, bronchial hyperresponsiveness, and airways inflammation. According to a review paper titled “Impact of Air Pollution on Asthma Outcomes” by Tiotiu et.al., air pollution hampered asthma outcomes in adults and children. Air pollution from traffic, nitrogen dioxide (NO2), and secondhand smoking (SHS) are all substantial risk factors for the development of asthma in children. Asthma symptoms, exacerbations, and decreased lung function can be triggered by exposure to outside pollution.
A new study financed by the Environmental Protection Agency (EPA) analyzed the link between air pollution and asthma. While experts cannot determine the primary asthma-causing agent due to air pollution, evidence suggests that it suppresses genes that control the immune system to distinguish between an allergen and a hazardous foreign substance, such as a virus or bacteria. The immune system then goes into overdrive, triggering an inflammatory reaction regardless of whether the drug is toxic, resulting in asthma.
Researchers from Stanford University's Children's Center investigated the effect of air pollution on two genes involved in immunological tolerance in children from an area with high levels of pollution. They discovered that short- and long-term exposure to high amounts of carbon monoxide (CO), NO2, and PM2.5 (particulate matter) were linked to changes in these two genes, which caused asthma. These findings focused on the epigenetic impacts of air pollution exposure and could help in the development of preventative asthma medicines.
Each of these asthma research has improved the understanding of asthma in children and supplied crucial information to the EPA that can be used to protect human health and the environment. Through these research works, the drug discovery and development for asthma is being expedited which is driving the asthma drug market.
SOUTH AND CENTRAL AMERICA ASTHMA DRUGS MARKET SEGMENTATION
The South and Central America asthma drugs market, by medication, is segmented into quick relief medications and long-term control medications. Based on route of administration, the South and Central America asthma drugs market is segmented into inhaled, prefilled syringe/vials, and others. Based on distribution channel, the South and Central America asthma drugs market is segmented into online pharmacies, hospital pharmacies, retail pharmacies and drugstores Geographically, the South and Central America asthma drugs market is divided into Brazil, Argentina and Rest of South and Central America.
AstraZeneca, TEVA PHARMACEUTICAL INDUSTRIES LTD, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Merck & Co., Inc., Koninklijke Philips N.V., Sanofi, Pfizer Inc. (Arena Pharmaceutical GmbH), Novartis AG and Abbott are among the leading companies operating in the South and Central America asthma drugs market.